Food Supplement Industry Pushes Congress on CBD Product Sales

CBD products have become immensely popular in the preceding decade, owing to the host of medical benefits that users get. For a long time, people shied away from cannabidiol due to its connection to THC, but that’s slowly changed over the years. Last year the Farm Bill was passed, and it legalized the industrial cultivation of hemp from where CBD is extracted. However, the industry has been plagued by a lack of regulations, and Congress is under even more pressure to speed up their efforts in crafting suitable legislation for the industry.

Four trade associations representing the dietary supplement industry sent a letter urging policymakers to take swift action to ensure the lawful marketing of CBD products while the FDA crafts regulations.

The letter was signed by the American Herbal Association, Consumer Healthcare Products Association, Council for Responsible Nutrition, and the United Natural Products Alliance. It implored the legislators to clarify that CBD derived from the hemp plant is a lawful dietary ingredient if the dietary supplement containing CBD meets all the established product safety and quality criteria.

To achieve this, the group recommended granting a limited waiver that would exempt CBD products from a provision of the Food, Drug, and Cosmetics Act. Being exempt would then allow CBD merchants to sell their products as dietary supplements as long as the hemp-derived product meets all health and safety standards.

The letter states that given the very rapidly growing marketplace of products, Congress must take swift action to clarify the legal status of hemp-derived CBD dietary supplements. It adds that it is equally essential for the FDA to have enough resources to shield the public from subpar and unsafe CBD products.

The increasingly high demand for CBD and CBD products necessitates quick action. The growth in product sales increases the need for clarity among the consumers, retailers, and manufacturers about the legal status of these products. The letter states that FDA officials indicated that without any Congressional push, it would take up to five years to craft regulations. The team also showed approval for the agricultural spending legislation approved by the Senate that would allocate the FDA $1.2 million to finance their efforts to develop suitable cannabis regulations.

This wasn’t the first time the FDA has been called out on its sluggish pace. Recently, a bipartisan coalition of senators led by Senate Majority leader Mitch McConnell urged the FDA to clear a path to allow for the lawful marketing of CBD products while it continues to develop legislation.

Experts believe CBD industry players like Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) and IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) look forward to hearing what the lawmakers have to say about the calls in the letter.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

Archives

Select A Month

CBDWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722